VentiRx Pharmaceuticals' Novel TLR8 Agonist, VTX-2337, Successfully Completes Phase 1 Clinical Trial in Oncology

October 5, 2010

PR Newswire

SAN DIEGO and SEATTLE, Oct. 4 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the successful completion of a Phase 1 clinical study for VTX-2337, its novel TLR8 agonist for oncology at the International Society for Biological Therapy of Cancer (ISBTC). In a poster entitled "First-in-Man Phase I Clinical Trial of VTX-2337—A Selective Toll-Like Receptor 8 (TLR8) Agonist—In Oncology Patients," VTX-2337 was proven to be safe and well tolerated with a predictable pharmacokinetic profile in 33 patients. In addition, VTX-2337 showed dose-dependent pharmacologic activity.

Additionally, George Coukos, M.D., Ph.D., Associate Chief of the Division of Gynecologic Oncology and Director of the Ovarian Cancer Research Center at the University of Pennsylvania Abramson Cancer Center presented preclinical data combining VTX-2337 with Doxil chemotherapy in a poster also at ISBTC entitled "TLR8 Agonist and Doxil chemotherapy potently activate human antitumor immune response in a human immune system mouse model." Read More